Key result
ADIPOQ rs266729 GG genotype is linked to ~137% higher gestational hypertension risk versus CC.
Why the study?
ADIPOQ polymorphisms are linked to gestational hypertension and preeclampsia, but no prior study had examined whether ADIPOQ SNPs and haplotypes affect adiponectin levels in hypertensive disorders of pregnancy.
Do ADIPOQ polymorphisms and haplotypes affect circulating adiponectin levels and susceptibility to gestational hypertension and preeclampsia?
Case-Control (n=436)
No
Do ADIPOQ polymorphisms and haplotypes affect circulating adiponectin levels and susceptibility to gestational hypertension and preeclampsia?
Odds Ratio: 2.366 (95% CI 1.154–4.816)
p-value: p=0.0346
ADIPOQ polymorphisms and haplotypes are associated with altered circulating adiponectin levels and may influence susceptibility to hypertensive disorders of pregnancy.
ADIPOQ variants may influence HDP susceptibility and adiponectin levels; leaves open whether genotyping informs risk stratification or therapy.
Introduction Imbalance of adipocytokines has been implicated in endothelial dysfunction in hypertensive disorders of pregnancy (HDP). Adiponectin is an adipocytokine that regulates metabolism, insulin sensitivity, and inflammation, and increased adiponectin levels have been associated with mortality in subjects with cardiovascular diseases. Adiponectin also plays a role in trophoblast invasion during placental development. ADIPOQ gene has polymorphisms that modulate adiponectin levels and are linked to several diseases, including gestational hypertension (GH) and preeclampsia (PE). However, no previous study has examined whether ADIPOQ SNPs and haplotypes affect adiponectin levels in HDP. Objectives We assessed and compared plasma adiponectin levels among healthy pregnant (HP, n = 182), GH (n = 121), and PE (n = 133) women, and examined whether ADIPOQ SNPs rs266729, rs2241766 and rs1501299, and their haplotypes are associated with susceptibility to HDP; and whether these polymorphisms and haplotypes affect adiponectin levels in HP, GH and PE. Materials and Methods Adiponectin concentrations were determined using the Human Adiponectin ELISA kit. Genotypes were determined by Taqman allele discrimination assays. Haplotype frequencies were estimated using Haplo. stats. Multiple logistic/linear regression analyses were adjusted for selected covariates. Results Plasma adiponectin levels were higher in PE than in HP, including when patients were stratified by body mass index. Regarding rs266729 (C>G) SNP, the GG genotype was associated with risk for GH, and the CG genotype may protect against PE. PE patients carrying the CG and GG genotypes showed higher adiponectin levels than their CC counterparts. The ‘G,T,G’ haplotype showed higher adiponectin levels in PE than in HP, and the ‘C,T,T’ haplotype may protect against GH. Conclusion Our novel findings indicate that ADIPOQ polymorphisms and haplotypes may affect circulating adiponectin levels and the susceptibility to GH and PE.
No takes yet. Share an insight, caveat, or question.
Castro et al. (2026) conducted a case-control in Gestational hypertension and preeclampsia (n=436). ADIPOQ rs266729 GG genotype vs. ADIPOQ rs266729 CC genotype was evaluated on Risk of gestational hypertension (OR 2.366, 95% CI 1.154-4.816, p=0.0346). The ADIPOQ rs266729 GG genotype was associated with an increased risk of gestational hypertension (OR 2.366) compared to the CC genotype, and affected circulating adiponectin levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: